| |
|
|
|
|
|
This test is not appropriate for patients with prolonged aPTT results. By performing the APTT-based APC resistance assay in the presence of an excess of factor V deficient plasma, the sensitivity and specificity for the factor V:Q506 mutation is significantly increased.
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Anti-Annexin V Antibody
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Anti-Cardiolipin Antibody
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Antiplatelet Antibody - Direct
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Antiplatelet Antibody - Indirect
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Antithrombin III Activity
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
aPTT-LA
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Mixing Studies (APTT)
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Thrombin Time
|
Company:
Date:
January 28, 2009
|
|
|
|
|
|
|
|
|
|
Thrombin/Antithrombin Complex
|
Company:
Date:
January 28, 2009
|
|
|
|
|